在基于吉西他滨的放化疗中加入深部热疗，可能会提高不可切除的局部晚期胰腺癌患者的生存率。
The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas.
作者信息
Rogers S J, Datta N R, Puric E, Timm O, Marder D, Khan S, Mamot C, Knuchel J, Siebenhüner A, Pestalozzi B, Guckenberger M, Bodis S, Riesterer O
机构信息
Centre for Radiation Oncology KSA-KSB, Kantonsspital Aarau, 5001 Aarau, Switzerland.
Department of Medical Oncology and Haematology, Kantonsspital Aarau, Tellstrasse, 5001 Aarau, Switzerland.
出版信息
Clin Transl Radiat Oncol. 2021 Jan 25;27:109-113. doi: 10.1016/j.ctro.2021.01.008. eCollection 2021 Mar.
INTRODUCTION
Driven by the current unsatisfactory outcomes for patients with locally advanced pancreatic cancer (LAPC), a biologically intensified clinical protocol was developed to explore the feasibility and efficacy of FOLFORINOX chemotherapy followed by deep hyperthermia concomitant with chemoradiation and subsequent FOLFORINOX chemotherapy in patients with LAPC.
METHODS
Nine patients with LAPC were treated according to the HEATPAC Phase II trial protocol which consists of 4 cycles of FOLFORINOX chemotherapy followed by gemcitabine-based chemoradiation to 56 Gy combined with weekly deep hyperthermia and then a further 8 cycles of FOLFORINOX chemotherapy.
RESULTS
One grade three related toxicity was reported and two tumours became resectable. The median overall survival was 24 months and 1 year overall survival was 100%.
CONCLUSIONS
Intensification of chemoradiation with deep hyperthermia was feasible in nine consecutive patients with LAPC.
引言
鉴于目前局部晚期胰腺癌（LAPC）患者的治疗效果不尽人意，我们制定了一项生物强化临床方案，以探讨FOLFORINOX化疗联合深部热疗同步放化疗及后续FOLFORINOX化疗在LAPC患者中的可行性和疗效。
方法
9例LAPC患者按照HEATPAC II期试验方案进行治疗，该方案包括4个周期的FOLFORINOX化疗，随后进行以吉西他滨为基础的同步放化疗至56 Gy，同时每周进行深部热疗，然后再进行8个周期的FOLFORINOX化疗。
结果
报告了1例3级相关毒性反应，2例肿瘤变为可切除。中位总生存期为24个月，1年总生存率为100%。
结论
在9例连续的LAPC患者中，深部热疗强化放化疗是可行的。
Zotero 插件